Psychedelic Weekly Headlines | September 2nd

September 2, 2022

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

PharmAla Biotech ($MDMA) filed a patent application for 6 MDMA analogs and has been selected as the MDMA manufacturing partner for The University of Sydney's upcoming Phase II clinical trial. Details

Cybin ($CYBN) announced first patient dosing in their Phase I/IIa trial evaluating CYB003, a proprietary deuterated psilocybin analog, as a potential treatment for major depressive disorder. Press Release

Lobe Sciences ($LOBE | $LOBEF) entered into an investment agreement with Cantheon Capital to fund $1.5M USD toward clinical trials in Australia. Lobe Sciences will conduct three clinical trials evaluating their proprietary psilocin analogues. Press Release

Optimi Health ($OPTI | $OPTHF) entered into an international psilocybin supply agreement with Promises Innovative Recovery, a research and educational center focused on innovative treatments with psychedelic-assisted psychotherapy. Press Release

Filament Health ($FH | $FLHLF) began dosing patients with their natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA Journey Centers' psychedelic-assisted therapist training program. Press Release

Mindset Pharma ($MSET | $MSSTF) identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds, further expanding their IP portfolio. Press Release

Core One Labs ($COOL | $CLABF) initiated rollout of their commercial sales strategy for their proprietary biosynthetic API psilocybin product. Press Release

Wesana Health ($WESA | $WSNAF) announced the sale of their clinic management assets for USD$2,100,000 as part of an effort to strengthen their balance sheet and streamline the company. Press Release

Mydecine Innovations ($MYCO | $MYCOF) signed a LOI to sell its wholly-owned subsidiary, Mindleap Health, to PanGenomic Health for a purchase price of C$4,000,000. Press Release


ARK Invest: How “Far Out” Are Psychedelic Therapeutics?

Forbes: Psychedelics And Mental Health: What Does The Science Say?

Psychology Today: Why Psychedelics May Be the Future of Health Care

VICE: The Trippy History of Magic Mushrooms

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.